Search
Navafenterol
go.drugbank.com/drugs/DB19195InvestigationalNavafenterol is under investigation in clinical trial NCT02971293 (Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871).
Cannabidiolic acid
go.drugbank.com/drugs/DB19261InvestigationalCannabidiolic acid is under investigation in clinical trial NCT04103814 (Effect of Topical CBD Cream for Degenerative Hallux Disorders).
IDM-1
go.drugbank.com/drugs/DB05292ExperimentalIt is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc. … IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer.
SR-9009
go.drugbank.com/drugs/DB14013ExperimentalSR-9009 is a REV-ERB agonist. … SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues
Prostaglandin G2
go.drugbank.com/drugs/DB03866ExperimentalA cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]
AMP-201
go.drugbank.com/drugs/DB18663ExperimentalAMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.
GLPG-1205
go.drugbank.com/drugs/DB15346InvestigationalGLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)).
ALT-P1
go.drugbank.com/drugs/DB18485InvestigationalALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.
RD13-02
go.drugbank.com/drugs/DB27110InvestigationalRD13-02 is a biologic drug. RD13-02 is under investigation in clinical trial NCT05923541 (RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies).
Ciraparantag
go.drugbank.com/drugs/DB15199InvestigationalCiraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban).